PSYCHOTHERAPY VERSUS PHARMACOTHERAPY FOR POSTTRAUMATIC STRESS DISORDER: SYSTEMIC REVIEW AND META-ANALYSES TO DETERMINE FIRST-LINE TREATMENTS

Depression and Anxiety

Volumn 33, Issue 9, 2016, Pages 792-806

  Lee, Daniel J ^a,b   Schnitzlein, Carla W ^b,c   Wolf, Jonathan P ^d   Vythilingam, Meena ^e   Rasmusson, Ann M ^f   Hoge, Charles W ^g  

^a JBSA Fort Sam Houston ^*  (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c Bayne Jones Army Community Hospital   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e US Marine Corps   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Australian; Department of Defense; International Society for the Study of Traumatic Stress; ISTSS; National Institute for Clinical Excellence; NICE; pharmacotherapy; posttraumatic stress disorder; psychotherapy; PTSD; VA DoD; WHO; World Health Organization

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BROFAROMINE; CITALOPRAM; FLUOXETINE; GUANFACINE; MIRTAZAPINE; NEFAZODONE; OLANZAPINE; PAROXETINE; PLACEBO; PRAZOSIN; RISPERIDONE; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE;

COGNITIVE BEHAVIORAL THERAPY; COGNITIVE PROCESSING THERAPY; COGNITIVE RESTRUCTURING; COMORBIDITY; DRUG EFFICACY; EFFECT SIZE; EYE MOVEMENT DESENSITIZATION AND REPROCESSING; FOLLOW UP; HUMAN; IMAGINAL EXPOSURE THERAPY; INTERPERSONAL THERAPY; MAJOR DEPRESSION; OUTCOME ASSESSMENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROLONGED EXPOSURE THERAPY; PSYCHOTHERAPY; REVIEW; STRESS INOCULATION TRAINING; STRUCTURED INTERVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84985943126     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22511     Document Type: Review

References (79)

1. PTSD Management Working Group. VA/DoD Clinical Practice Guidelines for Post-Traumatic Stress Disorder. Washington, DC: Department of Defense and the Veteran's Association (DoD/VA); 2010.
2. Gaskell, British Psychological Society. Post-traumatic stress disorder: The management of PTSD in adults and children in primary and secondary care. National Clinical Practice Guideline Number 26. Wilshire, England: Cromwell Press Ltd; 2005.
3. International Society for Traumatic Stress Studies Board of Directors. Effective Treatments for PTSD. 2nd ed. Oakbrook Terrace, IL: Guilford Press; 2005.
4. Australian Centre for Posttraumatic Mental Health. The Australian Guidelines for the Treatment of Acute Stress Disorder and Posttraumatic Stress Disorder. Melborne, Australia: Australian Centre for Posttraumatic Mental Health (ACPMH); 2013.
5. World Health Organization. Guidelines for the Management of Conditions Specifically Related to Stress. Geneva, Switzerland: World Health Organization Press (WHO Press); 2013.
6. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. Arlington, VA: American Psychiatric Association (APA); 2004.
7. Bisson J, Roberts N, Andrew M, Cooper R, Lewis C. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Rev 2013.
8. Stein D, Ipser J, Seedat S. Medication for post traumatic stress disorder. Cochrane Rev 2006.
9. Hoskins M, Pearce J, Bethell A, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry 2015;206(2):93–100.
10. Institute of Medicine. Treatment for Posttraumatic Stress Disorder in Military and Veteran Populations: Final Assessment. Washington, DC: The National Academies Press; 2014.
11. Steenkamp M, Litz B, Hoge C, Marmar C. Psychotherapy for military-related PTSD. J Am Med Assoc 2015;314(5):489–500.
12. Jonas DE, Cusack K, Forneris CA, et al. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD). Comparative Effectiveness Review No. 92. (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I.) AHRQ Publication No. 13-EHC011-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
13. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(6):e1000097.
14. Hoge C, Grossman S, Auchterlonie J, Riviere L, Milliken C, Wilk J. PTSD treatment for soldiers after combat deployment: low utilization of mental health care and reasons for dropout. Psychiatr Serv 2014;65(8):997–1004.
15. Davidson J, Kudler H, Smith R, et al. Treatment of Posttraumatic Stress Disorder With Amitriptyline and Placebo. Arch Gen Psychiatry 1990;47:259–266.
16. Davidson J, Weisler R, Butterfield M, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003;53:188–191.
17. Connor K, Davidson J, Weisler R, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 2006;184:21–25.
18. Butterfield M, Becker M, Connor K, Sutherland S, Churchill L, Davidson J. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001;16(4):197–203.
19. Higgins J, Altman D, Gotzsche P, Juni P, Moher D. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J 2011;343(d5928).
20. Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care 1989;27(Suppl 3):S178–S189.
21. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557–560.
22. Gleser L, Olkin I. Models for Estimating the Number of Unpublished Studies. Stanford Department of Statistics: Stanford University; 1995.
23. Blanchard E, Hickling E, Devineni T, et al. A controlled evaluation of cognitive behaviorial therapy for posttraumatic stress in motor vehicle accident survivors. Behav Res Ther 2003;41:79–96.
24. Blanchard E, Hickling E, Malta L, et al. One- and two-year prospective follow-up of cognitive behavior therapy or supportive psychotherapy. Behav Res Ther 2004;42:745–759.
25. Martenyi F, Brown E, Zhang H, Koke S, Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 2002;181:315–320.
26. Martenyi F, Brown E, Zhang H, Prakash A, Koke S. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 2002; 63(3):199–206.
27. Brady K, Pearlstein T, Asnis G, Baker D, Rothbaum B. Efficacy and safety of sertraline treatment of posttraumatic stress disorder. J Am Med Assoc 2000;283(14):1837–1844.
28. Davidson J, Pearlstein T, Londborg P, Brady K, Rothbaum B. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001;158:1974–1981.
29. Davidson J, Rothbaum B, van der Kolk B, Sikes C, Farfel G. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001;58:485–492.
30. Naylor J, Kilts J, Bradford D, et al. A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. Int Clin Psychopharmacol 2015;30:167–174.
31. Baker D, Diamond B, Gillette G, et al. A Double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology 1995;122:386–389.
32. Katz R, Lott M, Arbus P, et al. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety 1995;1:169–174.
33. Becker M, Hertzberg M, Moore S, Dennis M, Bukenya D, Beckham J. A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol 2007;27:193–197.
34. McDonagh A, Friedman M, McHugo G, et al. Randomized trial of cognitive–behavioral therapy for chronic posttraumatic stress disorder in adult female survivors of childhood sexual abuse. J Consult Clin Psychol 2005;73(3):515–524.
35. Tucker P, Potter-Kimball R, Wyatt D, et al. Can Physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull 2003;37(3):135–149.
36. Suris A, Link-Malcolm J, Chard K, Ahn C, North C. A randomized clinical trial of cognitive processing therapy for veterans with PTSD related to military sexual trauma. J Trauma Stress 2013;26:28–37.
37. Davis L, Davidson J, Ward C, Bartolucci A, Bowden C, Petty F. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008;28:84–88.
38. Hamner M, Faldowski R, Robert S, Ulmner H, Horner M, Lorberbaum J. A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatry 2009;21(2):89–94.
39. Carlson J, Cherntob C, Rusnak K, Hedlund N, Muraoka M. Eye movement desensitization and reprocessing (EDMR) treatment for combat-related posttraumatic stress disorder. J Traum Stress 1998;11(1):3–24.
40. Taylor S, Thordarson D, Maxfield L, Fedoroff I, Lovell K, Ogrodniczuk J. Comparative efficacy, speed, and adverse effects of three PTSD treatments: exposure therapy, EMDR, and relaxation training. J Consult Clin Psychol 2003;71(2):330–338.
41. Davidson J, Connor K, Hertzber M, Weisler R, Wilson W. Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacology 2005;25(2):166–169.
42. van der Kolk B, Spinazzola J, Blaustein M, Hopper J, Hopper E. A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J Clin Psychiatry 2007;68:37–46.
43. Martenyi F, Brown E, Caldwell C. Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J Clin Psychopharmacol 2007;27:166–170.
44. Martenyi F, Soldatenkova V. Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial. Eur Neuropsychopharmacol 2006;16:340–349.
45. Davis L, Ward L, Rasmusson A, Newell J, Frazier E. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychol Bull 2008;41(1):8–18.
46. Neylan T, Lenoci M, Samuelson K, et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006;163(12):2186–2188.
47. Markowitz J, Petkova E, Neria Y, et al. Is exposure necessary? A randomized clinical trial of interpersonal psychotherapy for PTSD. Am J Psychiatry 2015;172(5):430–440.
48. Davis L, Jewell M, Ambrose S, et al. A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol 2004;24(3):291–297.
49. Carey P, Suliman S, Ganesan K, Seedat S, Stein D. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol Clin Exp 2012;27:386–391.
50. Stein M, Kline N, Matloff J. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind placebo-controlled study. Am J Psychiatry 2002;159:1777–1779.
51. GlaxoSmithKline. A study of the maintained efficacy and safety of paroxetine versus placebo in the long-term treatment of posttraumatic stress disorder. Unpublished 2001.
52. Marshall R, Beebe K, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001;158:1982–1988.
53. Marshall R, Lewis-Fernandez R, Blanco C, et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety 2007;24:77–84.
54. Schneier F, Neria Y, Pavlicova M, Hembree E, Jung Suh E. Combined prolonged exposure therapy and paroxetine for PTSD related to the world trade center attack: a randomized controlled trial. Am J Psychiatry 2012;169:80–88.
55. Tucker P, Zaninelli R, Yehunda R, Ruggiero L, Dillingham K, Pitts C. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62(11):860–868.
56. Fani N, Kitayama N, Ashraf A, et al. Neuropsychological functioning in patients with posttraumatic stress disorder following short-term paroxetine treatment. Psychopharmacol Bull 2009;42(1):53–68.
57. Fani N, Ashraf A, Afzal N, et al. Increased Neural response to trauma scripts in posttraumatic stress disorder following paroxetine treatment: a pilot study. Neurosci Lett 2011;491(3):196–201.
58. Bryant R, Moulds M, Guthrie R, Dang S, Nixon R. Imaginal exposure alone and imaginal exposure with cognitive restructuring in treatment of posttraumatic stress disorder. J Consult Clin Psychol 2003;71(4):706–712.
59. Marks I, Lovell K, Noshirvani H, Livanou M, Thrasher S. Treatment of posttraumatic stress disorder by exposure and/or cognitive restructuring. Arch Gen Psychiatry 1998;55:317–325.
60. Foa E, Rothbaum B, Riggs D, Murdock T. Treatment of posttraumatic stress disorder in rape victims: a comparison between cognitive-behavioral procedures and counseling. J Consult Clin Psychol 1991;59(5):715–723.
61. Rauch S, King A, Abelson J, et al. Biological and symptom changes in posttraumatic stress disorder treatment: a randomized clinical trial. Depress Anxiety 2015;32:204–212.
62. Schnurr P, Friedman M, Engel C, et al. Cognitive behavioral therapy for posttraumatic stress disorder in women: a randomized controlled trial. J Am Med Assoc 2007;297(8):820–830.
63. Raskind M, Peskind E, Kanter E, Petrie E, Radant A. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003;160:371–373.
64. Raskind M, Peterson K, Williams T, Hoff D, Hart K. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry 2013;170:1003–1010.
65. Raskind M, Peskind E, Hoff D, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007;61:928–934.
66. Bartzokis G, Lu P, Turner J, Mintz J, Saunders C. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2004;57:474–479.
67. Krystal J, Rosenheck R, Cramer J, Vessicchio J, Jones K. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD. J Am Med Assoc 2011;306(5):493–502.
68. Padala P, Madison J, Monnahan M, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006;21:275–280.
69. Reich D, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone in the treatment of possttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry 2004;65:1601–1606.
70. Rothbaum B, Killeen T, Davidson J, Brady K, Connor K. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry 2008;69:520–525.
71. Davidson J, Rothbaum B, Tucker P, Asnis G, Benattia I, Musgnung J. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 2006;26:259–267.
72. Friedman M, Marmar C, Baker D, Sikes C, Farfel G. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a department of veterans affairs setting. J Clin Psychiatry 2007;68(5):711–720.
73. Zohar J, Amital D, Miodownik C, et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002;22(2):190–195.
74. Davidson J, Brady K, Mellman T, Stein M, Pollack M. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007;27(1):85–88.
75. Tucker P, Trautman R, Wyatt D, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:201–206.
76. Yeh M, Mari J, Costa M, Andreoli S, Bressan R, Mello M. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther 2011;17:305–310.
77. Davidson J, Baldwin D, Stein D, Kuper E, Benattia I, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006;63:1158–1165.
78. Raskind M, Peskind E. CSP No. 563, Prazosin and Combat Trauma PTSD (PACT) Study. Available at: http://www.research.va.gov/programs/csp/csp563.cfm (accessed March 21, 2016).
79. Zatzick D. Toward the estimation of population impact in early posttraumatic stress disorder intervention trials. Depress Anxiety 2012;29:79–84.